Point72 Asset Management, L.P.
Position in ALLO — Allogene Therapeutics, Inc.
CIK 1603466
STAMFORD, CT
Position in ALLO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$540,057
+$397,934 QoQ
Shares Held
221,335
+113.4% QoQ
Ownership
0.064%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
6 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ALLO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Point72 Asset Management, L.P. holds $2,394,472,979 across 188 Biotechnology names. ALLO ranks #141 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APLS |
Apellis Pharmaceuticals, Inc.
|
4,183,918 | $168,319,021 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
225,510 | $118,047,719 | |
| 3 | CLDX |
Celldex Therapeutics, Inc.
|
3,229,939 | $102,453,665 | |
| 4 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
846,801 | $73,646,282 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
424,750 | $71,791,245 | |
| 6 | ABVX |
Abivax S.A.
|
637,736 | $71,011,903 | |
| 7 | LEGN |
Legend Biotech Corp
|
3,886,017 | $70,298,047 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
358,634 | $67,799,757 |
All Filings in ALLO
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $540,057 | 221,335 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $142,123 | 103,740 | Shares | Defined | 2026-02-17 | |
| 2023-12-31 | $2,181,092 | 679,468 | Shares | Defined | 2024-02-14 | |
| 2023-06-30 | $11,018 | 2,217 | Shares | Defined | 2023-08-14 | |
| 2023-03-31 | $10,364 | 2,098 | Shares | Defined | 2023-05-15 | |
| 2022-09-30 | $3,166,560 | 293,200 | Shares | Defined | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||